The Role of Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia: Past, Present, and Future Directions

Relapsed and/or refractory (R/R) acute myeloid leukemia (AML) is hallmarked by dramatic prognosis. Treatment remains challenging, with allogeneic hematopoietic stem cell transplantation (HSCT) as the only curative option. The BCL-2 inhibitor venetoclax (VEN) has proven to be a promising therapy for...

Descripción completa

Detalles Bibliográficos
Autores principales: Piccini, Matteo, Mannelli, Francesco, Coltro, Giacomo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10215478/
https://www.ncbi.nlm.nih.gov/pubmed/37237661
http://dx.doi.org/10.3390/bioengineering10050591

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10215478/
https://www.ncbi.nlm.nih.gov/pubmed/37237661
http://dx.doi.org/10.3390/bioengineering10050591

Ejemplares similares